Trading Statement Q1-2025: A Landmark Deal for GUBamy

May 9, 2025 2:00 AM

Gubra (CPH:GUBRA) - Today, Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement to AbbVie for our anti-obesity asset GUBamy (Amylin). A landmark deal worth USD 2.2 billion in upfront and milestones plus royalties. As part of our strategy toward 2030, we also diverted more resources in the quarter to our D&P business. For the CRO business, revenue amounted DKK 51 million,...

Read more

Genflow Biosciences PLC Announces Share Subscription, Director's Dealing and Update

May 9, 2025 2:00 AM

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), is pleased to announce that it has raised gross proceeds of £500,000 (before expenses) via an allotment to Eric Leire of 62,500,000 new ordinary shares of £0.0003 each ("New Ordinary Shares") at an issue price of 0.8 pence (being the bid price as at close of business on 8 May 2025) (the "Issue Price").The net proceeds of this fundraise will be used to advance a...

Read more

PATH EX, Inc. Announces Successful $5 Million Financing Round to Advance CycloPE, a Breakthrough Treatment for Sepsis

May 8, 2025 5:30 PM

PATH EX, Inc., a medical device company located in the Texas Medical Center Innovation Factory, is excited to announce the successful completion of a $5 million financing round. This investment was led by IAG Capital Partners and supported by the TMC Venture Fund and Fitz Gate Ventures. The capital raised will accelerate the development and future commercialization of CycloPE®, a medical device designed to rapidly eradicate bacteria from the...

Read more

Alpha Genesis CEO Reaffirms Commitment to "Make America Healthy Again" Initiative

May 8, 2025 5:00 PM

Dr. Greg Westergaard, CEO of Alpha Genesis Incorporated (AGI), today reaffirmed the company's continued support for the federal Make America Healthy Again initiative, describing it as a "critical framework" for aligning scientific innovation with national well-being.Launched earlier this year, the initiative aims to accelerate medical progress, strengthen the nation's biomedical infrastructure, and promote public health through evidence-based...

Read more

A Second Chance at a Second Chance: Rick Searches for a Kidney Transplant

May 8, 2025 2:05 PM

For more than a decade, Rick Mendoza had been fully enjoying his kidney transplant. From hikes to mowing the lawn to attending his daughter's school and sporting events, his transplant let him experience all of the simple pleasures in life. That was until his kidneys started to fail again in 2022."I thought to myself, ‘This cannot be happening. Not again. Not already,'" said Rick.The Gift of Life: Kidney DonationBack in 2010, Rick's kidneys...

Read more

Telcion Named "Best Overall Healthcare Cybersecurity Solution" in 2025 MedTech Breakthrough Awards Program

May 8, 2025 11:15 AM

Telcion Communications Group, a trusted provider of IT solutions and managed services tailored to healthcare's critical needs, has been named the winner of the "Best Overall Healthcare Cybersecurity Solution" awardin the 9th annual MedTech Breakthrough Awards. The independent market intelligence organization, MedTech Breakthrough, presents these prestigious awards recognizing the top companies, technologies, and products in the global digital...

Read more

Vault Cares Network Partners With PlacidWay to Expand Global Access to Affordable, High-Quality Healthcare

May 8, 2025 11:00 AM

Vault Cares Network, a trusted ally in navigating complex healthcare, offering expert second opinions and access to world-class providers and powered by Vault Strategies, is proud to announce its new partnership with PlacidWay, a global leader in medical tourism and international healthcare facilitation. Together, the organizations will offer expanded access to world-class medical treatments and cost-saving options for patients seeking care...

Read more

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

May 8, 2025 9:30 AM

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") is proud to be celebrating National Pet Cancer Awareness Month, a time devoted to raising awareness about cancer in pets, particularly in dogs and cats."According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer,"1 said Lisa Conte, Jaguar's founder, president, and CEO....

Read more

CORRECTION FROM SOURCE: Wellgistics Health Secures $50M ELOC Facility for XRP Treasury Reserve and Real-Time Payments Infrastructure and Other General Ops

May 8, 2025 9:25 AM

Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this...

Read more

Earth Day Focus for Gilead Sciences - Every Action Has an Impact

May 8, 2025 9:00 AM

Creating a healthier world for all starts with taking care of the one we all share. As one of America's Greenest Companies, we're always working to ensure our medicines are delivered in ways that safeguard the planet.Gilead SciencesGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care...

Read more

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

May 8, 2025 8:45 AM

Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today provided a program update for APVO711, a dual mechanism bispecific utilizing the PD-L1 arm to block the PD-1/PD-L1 pathway and the CD40 arm to enhance T cell priming through activation of the stimulatory receptor CD40 on antigen...

Read more

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

May 8, 2025 8:00 AM

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that its Board of Directors has approved the planned acquisition of SKNY Pharmaceuticals, Inc. (the "Merger"), following the completion of independent valuation reports on both companies. The Merger remains subject to MIRA and SKNY's...

Read more

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

May 8, 2025 8:00 AM

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on May 21 at 2:30 PM Eastern. Investors and other interested individuals may access the virtual presentation here:...

Read more

Interactive Strength Inc. (Nasdaq:TRNR) Responds to FAQ's About Sportstech's LTM Revenue of $54M and EBITDA of $5M through April 2025

May 8, 2025 7:50 AM

AUSTIN, TX / ACCESS Newswire / May 8, 2025 / Interactive Strength Inc. (NASDAQ:TRNR) ("TRNR" or the "Company"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands and pending acquirer of Sportstech and Wattbike, today announced that it has updated its investor FAQ's on its investor website in response to shareholder questions on yesterday's updates about Sportstech's LTM financial performance.For more commentary,...

Read more

Wellgistics Health Secures $50M Credit Facility and Launches XRP-Powered Payment Initiative

May 8, 2025 7:05 AM

Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this...

Read more

Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025

May 8, 2025 7:00 AM

Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:Bernstein's 41st Annual Strategic Decisions Conference (SDC), on Thursday, May 29th at 10:00am ETA live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website.investors.modernatx.com.A replay of each webcast will be archived on Moderna's website for at...

Read more

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo

May 8, 2025 6:30 AM

NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES) of the Ministry of Public Health (MSP), of the Democratic Republic of Congo (DRC). With this CNES approval, the proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection is cleared for further...

Read more

April Monthly Report - Continued Growth as We Approach 1,000 Active Units

May 8, 2025 2:00 AM

iZafe Group (STO:IZAFE-B) - April was a month marked by concrete expansion, deepened customer relationships, and sustained strong interest from new stakeholders. After a 12% increase in billable Dosell units in March, we grew by an additional 19% in April. This is a clear sign that our strategy is effective and that the need for digital medication management continues to rise. As it stands, we expect to reach an important milestone in May -...

Read more

Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director’s Dealing

May 8, 2025 2:00 AM

LONDON, UK / ACCESS Newswire / May 8, 2025 /IntroductionHemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised gross proceeds of £451,250 (before expenses) via an allotment to Vladislav Sandler of 250,000 new ordinary shares of £0.01 each ("New Ordinary Shares") at an issue price of 180.5p (being the bid price as at close of business on 7 May 2025) (the "Issue Price").The net proceeds of this fundraise will be...

Read more

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

May 7, 2025 4:15 PM

Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its third quarter of fiscal 2025, after the market close on Wednesday, May 14, 2025. The Company has scheduled a conference call and webcast that same day, Wednesday, May 14, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and...

Read more